Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Randomized, Observer-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Immunogenicity of Heptavalent mRNA-1975 (SR1-7) and Monovalent mRNA-1982 (SR1) in Parallel Against Lyme Disease in Healthy Participants 18 Through 70 Years of Age

NCT05975099 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT05975099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05975099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Randomized, Observer-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Immunogenicity of Heptavalent mRNA-1975 (SR1-7) and Monovalent mRNA-1982 (SR1) in Parallel Against Lyme Disease in Healthy Participants 18 Through 70 Years of Age
Lead sponsor
ModernaTX, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
July 26, 2023
Completion date
May 30, 2025
Enrollment
807 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

lyme disease